Updated: August 2026
CAR-T cell therapy is best known as a treatment for certain blood cancers. Researchers are now studying whether the same technology can help selected patients with severe autoimmune diseases by removing immune cells that contribute to persistent inflammation and organ damage.
The most encouraging evidence currently involves systemic lupus erythematosus, systemic sclerosis, also called scleroderma, and idiopathic inflammatory myopathies such as dermatomyositis. Research is also developing in rheumatoid arthritis, Sjögren’s syndrome, vasculitis, and other immune-mediated diseases.
However, CAR-T therapy for autoimmune disease is still an emerging and investigational treatment. The published studies remain relatively small, and the treatment is generally being considered for carefully selected patients with severe disease that has not responded to standard therapies.
Programs, protocols, and eligibility criteria may change. Every patient must be evaluated individually by an experienced medical team.
How May CAR-T Therapy Work in Autoimmune Disease?
Many autoimmune diseases involve abnormal B cells. These cells can produce autoantibodies and participate in immune reactions that attack the patient’s own tissues.
Most clinical experience to date has involved CD19-directed CAR-T cells. CD19 is a protein found on several stages of B-cell development.
The treatment generally involves:
- Collecting T cells from the patient’s blood.
- Genetically modifying the cells so they recognize CD19 or another selected target.
- Giving a short course of lymphodepletion chemotherapy
- Infusing the CAR-T cells back into the patient.
- Monitoring the patient closely for immune reactions, infections, and changes in blood counts.
The aim is to achieve deeper B-cell depletion than can usually be achieved with conventional antibody treatments. As new B cells eventually return, researchers hope that the immune system may rebuild without the same harmful autoimmune activity.
This process is sometimes described as an “immune reset.” Early evidence supports this possibility, but it is still too soon to know how reliably or permanently it occurs.
Read more patient testimonials >>
What Has Changed in the Evidence?
One of the most important recent developments was the publication of the phase 1/2a CASTLE study in Nature Medicine.
The study included 24 adults with severe, treatment-resistant autoimmune disease:
- Systemic lupus erythematosus
- Systemic sclerosis
- Idiopathic inflammatory myositis
At a median follow-up of approximately 13 months, all 24 patients were no longer receiving glucocorticoids or other immunosuppressive treatment.
Most patients with lupus achieved standard DORIS remission criteria. All patients with systemic sclerosis met the study’s clinical response threshold, and most patients with inflammatory myositis achieved a moderate or major response.
No higher-grade cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome was reported. Nevertheless, infections, disease flares during treatment preparation, and other complications remained important concerns.
These results are encouraging, but the study was an early-phase trial without a comparison group. The participants were carefully selected and had severe diseases that had not responded to several previous treatments.
Which Autoimmune Diseases Have the Strongest CAR-T Evidence?
Systemic Lupus Erythematosus
Lupus currently has some of the strongest early clinical evidence for CAR-T therapy in autoimmune disease.
Small studies have reported substantial reductions in disease activity, improvement in affected organs, disappearance or reduction of certain autoantibodies, and periods without steroids or other immunosuppressive medications.
Some patients have remained in remission after their B cells returned. This observation supports the immune-reset theory, but the number of treated patients is still limited, and the long-term risk of relapse remains uncertain.
Read more about CAR-T therapy for lupus.
Systemic Sclerosis (Scleroderma)
Systemic sclerosis affects the immune system, blood vessels, skin, and sometimes internal organs, particularly the lungs, heart, kidneys, and digestive system.
Early CAR-T studies have reported improvements in disease activity and skin involvement in selected patients.
It is important to distinguish active inflammation from permanent damage. CAR-T may help control immune activity, but it may not reverse fibrosis or organ damage that has already become irreversible.
Read more about CAR-T for systemic sclerosis (Scleroderma).
Inflammatory Myositis and Dermatomyositis
Inflammatory myopathies can cause severe muscle weakness and may also affect the lungs, skin, joints, and other organs.
Patients in early CAR-T studies have shown improvements in disease activity, muscle enzymes, and physical function. However, eliminating active inflammation may not completely restore muscles that have already sustained permanent damage.
Read more about CAR-T therapy for dermatomyositis.
Rheumatoid Arthritis
CAR-T therapy for rheumatoid arthritis is at an earlier stage of development.
Most people with rheumatoid arthritis can be treated with conventional disease-modifying drugs or biologic therapies. CAR-T research is mainly relevant to a much smaller group with severe, treatment-resistant disease.
Evidence from individual patients and early clinical research is encouraging, but it is not yet comparable with the evidence available for lupus.
Read more about CAR-T therapy for rheumatoid arthritis (RA).
Sjögren’s Syndrome, Vasculitis, and Other Diseases
Clinical research is expanding to Sjögren’s syndrome, certain forms of vasculitis, neurological autoimmune diseases, and other conditions involving abnormal B-cell activity.
Read more about CAR-T therapy for Sjögren’s Syndrome.
Is CAR-T an Established Treatment for Autoimmune Disease?
It is important to distinguish between established, emerging, and investigational uses.
- Established: CAR-T is an established treatment for selected blood cancers.
- Emerging: Autologous CD19 CAR-T for severe lupus, systemic sclerosis, and inflammatory myositis now has encouraging early clinical evidence.
- Investigational: CAR-T for other autoimmune diseases, donor-derived products, off-the-shelf CAR-T, and in-vivo CAR-T remain under clinical investigation.
Patients should be cautious about descriptions suggesting that CAR-T has already been proven to cure autoimmune disease. Some study participants have achieved treatment-free remission after a single infusion, but larger controlled studies are needed to determine how often this happens, which patients benefit, and how long remission may last.
What Are the Potential Risks?
CAR-T is an intensive medical treatment. Potential risks include cytokine release syndrome, neurological toxicity, infections, low blood counts, reduced antibody levels, complications from lymphodepletion chemotherapy, and disease flares during medication adjustments. Less common but serious complications may also occur.
The immune-related side effects reported in some autoimmune studies have been milder than those commonly seen in patients treated for advanced blood cancer. This does not mean that the treatment is risk-free.
Patients require careful preparation, monitoring, and follow-up by an experienced multidisciplinary team.
Read more about the major side effects of CAR-T therapy.
Who May Be Considered for Individual Review?
CAR-T evaluation may be relevant for selected patients whose autoimmune disease is severe, active, and resistant to several appropriate treatments.
The medical team may consider:
- The exact autoimmune diagnosis
- Current disease activity
- Previous medications and why they were stopped
- Kidney, lung, heart, nervous system, or other organ involvement
- Current infections and previous serious infections
- Blood counts and immune-system function
These are general considerations, not fixed eligibility rules. A website cannot determine whether a patient will be suitable or accepted. The treating medical team must review the complete medical history.
CAR-T Evaluation for International Patients in Israel
Selected patients with severe, treatment-resistant autoimmune or rheumatologic diseases may submit their medical records for individual review in Israel.
Submitting medical records does not guarantee that CAR-T therapy will be available, appropriate, or approved for a particular patient.
Read more about CAR-T treatment for rheumatologic diseases in Israel.
Israeli Hospitals can coordinate the submission of medical records and communication with the relevant medical team.
Submit your medical records through Israeli Hospitals for an individual review.
Sources
1. Hagen M, et al. “CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.” Nature Medicine, 2026.
2. Müller F, et al. “CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up.” New England Journal of Medicine, 2024.
3. Auth J, et al. “CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series.” The Lancet Rheumatology, 2025.
Links
Read patient testimonials
Initiating your CAR-T medical inquiry >>
